SureSeq myPanel™ NGS Custom AML Panel
Choose your perfect AML NGS panel from our range of fully tested and optimised panel content. Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs.
Find out more
For more information about any OGT product or service, please contact us.
Overview
SureSeq myPanel offers:
- Hybridisation-based panel delivering unparalleled coverage uniformity — detect low-frequency AML variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
- Pre-optimised panels that meet your technical requirements and work with your samples — no more laborious in-house optimisation, decreasing assay development time
- Bespoke panel content — sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
- Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites — get the most comprehensive insight into disease-driving mutations
Getting started with SureSeq myPanel NGS Custom AML Panel could not be simpler...
Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs.
Ordering Information
| Product | Contents | Cat. No. | Price |
|---|---|---|---|
| SureSeq myPanel NGS Custom AML Panel |
Enrichment baits; SureSeq Interpret Software | Various | Get a quote |
SureSeq: For research use only; not for use in diagnostic procedures.
Details
Acute myeloid leukaemia (AML) is the most common type of leukaemia in adults. Our understanding of AML has been transformed in recent years to a disease classified largely based on genetic, genomic and molecular characteristics. Key genes identified include CEBPA, NPM1 and FLT3, with mutations in several additional genes being of interest from recent research.
Excellent Uniformity of Coverage of the CEBPA Gene
Mutations in the CEBPA gene are among the most common molecular alterations in AML. Sequencing of the CEBPA gene is often hampered by a repetitive nucleotide sequence and a high GC-rich content, which can lead to technical challenges in assay design, requiring a supplementary fill-in with Sanger sequencing. OGT’s expert bait design overcomes these issues, to offer a high level of uniform coverage for a notoriously difficult gene to sequence (Figure 1).
Figure 1: Illustration of the excellent uniformity of coverage of the CEBPA gene averaging ~3000x coverage. Depth of coverage per base (grey). Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red). Repeat regions, and those rich in GC (pink).
Sophisticated Bait Design Strategies
Genes such as FLT3 contain internal tandem duplications (ITDs) that are challenging to target because they are by nature repetitive and can be very long and are generally masked in most panel designs. To provide optimal results, OGT employs sophisticated bait design strategies to create additional probes both up- and down-stream of the repetitive region. The length of these probes is customised to provide the same isothermal properties as other probes in the panel, leading to improved performance. This facilitates the capture of sequences around the repeat masked areas, and because of the read lengths, can read through short repetitive regions (Figure 2).
Figure 2: In this example, the FLT3 ITD’s are clearly visible, (A) 72 bp ITD, (B) wild type, (C) 30 bp ITD and (D) 126 bp ITD.
Getting started with your next SureSeq myPanel Custom Cancer Panel could not be simpler...
Select from any of the following myPanel AML gene or exonic content
| ASXL1 | ETV6 | IDH2 | NPM1 | TET2 |
| BCOR | FLT3 | KIT | NRAS | TP53 |
| CEBPA | GATA1 | KMT2A | PHF6 | WT1 |
| DNMT3A | IDH1 | KRAS | RUNX1 | U2AF1 |
A panel you may be interested in:
| Number | Gene | Number of exons |
| 1 | BCR-ABL1 | All |
| 2 | CEBPA | All |
| 3 | FLT3 | All |
| 4 | KIT | All |
| 5 | NPM1 | All |
| 6 | RUNX1 | All |
Talk to us about your custom AML NGS panel requirements and let our expertise work in helping advance your cancer research.
If you are looking for an extended myeloid panel choose our SureSeq Myeloid Panel covering 25 genes of interest.
Ordering Information
| Product | Contents | Cat. No. | Price |
|---|---|---|---|
| SureSeq myPanel NGS Custom AML Panel | Enrichment baits; SureSeq Interpret Software | Various | Get a quote |
| SureSeq Myeloid Panel (16 reactions) | Enrichment baits sufficient for 16 samples; SureSeq Interpret Software | 600075 | Get a quote |
| SureSeq Myeloid Panel (96 reactions) | Enrichment baits sufficient for 96 samples; SureSeq Interpret Software | 600076 | Get a quote |
| SureSeq NGS Library Preparation Kit (16) | Bundle of 1 x library preparation kit (16) containing adaptors, PCR primers and enzymes sufficient for 16 samples and 1 x SureSeq NGS Index Kit – Collection A | 500070 | Get a quote |
| SureSeq NGS Library Preparation Kit (48) | Bundle of 3 x library preparation kit (16), containing adaptors, PCR primers and enzymes sufficient for 48 samples and 1 x SureSeq NGS Index Kit – Collection B | 500073 | Get a quote |
| SureSeq NGS Index Kit - Collection A (16) | 16 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (16)] | 500071 | Get a quote |
| SureSeq NGS Index Kit - Collection B (48) | 48 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (48)] | 500072 | Get a quote |
For more information about the SureSeq AML NGS Panel or any cancer analysis products contact us at products@ogt.com.
We would like to thank UK NEQAS for providing OGT with validated research samples.
SureSeq: For research use only; not for use in diagnostic procedures.
Resources
Product profile
-
SureSeq myPanel™ NGS Custom AML Panels
-
SureSeq myPanel™ NGS Custom Breast Cancer panel
-
SureSeq myPanel™ NGS Custom Cancer Panels
-
SureSeq myPanel™ NGS Custom Colorectal Cancer Panel
-
SureSeq myPanel™ NGS Custom Melanoma Cancer Panel
-
SureSeq™ Core MPN Panel
-
SureSeq™ Myeloid Panel
-
SureSeq™ NGS Library Preparation Kit
Brochure
-
An integrated approach to profiling haematological disorders
For accurate detection of all types of genetic aberrations, various technologies are used. View OGT's integrated portfolio of products that allow the accurate analysis of haematological disorders.
-
An integrated approach to tumour profiling
Various technologies are available to study the mutations that cause cancer, but none is capable of accurate detection of all types of genetic aberrations. View OGT's integrated portfolio of products that allow the accurate analysis of solid tumours.
Flyer
Gene list
Lab Programme
Application note
-
Evaluation of enzymatic DNA digestion as an alternative to mechanical DNA fragmentation (sonication) for targeted NGS using the SureSeq™ Myeloid Panel
DNA fragmentation is a crucial first step in the preparation of libraries for NGS. In this application note, Oxford Gene Technology has evaluated an alternative method of fragmentation using the NEBNext® dsDNA Fragmentase®.
-
Selecting the best NGS enrichment assay for your needs
With NGS now in routine use for a broad range of research and clinical applications, this application note details the value of making the correct choice for the initial sequence enrichment step.
Catalogue
White paper
-
The role of NGS in stratified cancer medicine
In this white paper, two Clinical Scientists, Dr Matthew Smith and Dr George Burghel, share their views on the use of NGS in cancer genomics and its integration into the laboratory.
-
Understanding myeloid disorders with next-generation sequencing
How OGT’s SureSeq™ Myeloid Panel helps researchers identify and decipher the complex genetic origins of myeloproliferative disorders
Poster
-
Optimised, 1-day hybridisation-based NGS protocol yields 1% variant detection in MPN samples, as quickly and cost-effectively as multiplex PCR
Presented at AMP 2016, this poster outlines how the SureSeq™ Core MPN Panel can accurately detect alleles down to 1% variant allele fraction (VAF) in JAK2 (V617F) at a read depth of >1000x, facilitating reliable detection.
-
The accurate detection by next-generation sequencing (NGS) of difficult to sequence genes (CALR, CEBPA, FLT3) associated with myeloid disorders using a hybridisation-based enrichment approach
Presented at CGC 2017, this poster highlights the excellent uniformity of coverage obtained from the hybridisation-based enrichment using the SureSeq myPanel NGS Custom AML Panel.
-
The analysis of myeloproliferative neoplasm samples using a rapid (30 minute) hybridisation-based enrichment protocol for next-generation sequencing (NGS)
Presented at the CGC 2017 annual summer meeting in Denver, USA, this poster illustrates the excellent quality data generated by the OGT 1-day hybridisation-based SureSeq LPK protocol in combination with the SureSeq Core MPN Panel.
-
The application of a hybridisation-based next-generation sequencing (NGS) enrichment panel for the analysis of key genes involved in ovarian and breast tumours using DNA from FFPE samples
-
The application of a hybridisation-based NGS enrichment panel for the analysis of somatic variants in tumour samples and reference standards
Presented at AGT 2017, this poster outlines the application of a hybridisation-based NGS enrichment panel for the analysis of solid tumour somatic variants, demonstrating 100% concordance in variant detection in both genomic and formalin-compromised DNA.
-
The application of a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid (30 minute) hybridisation step
Presented at AGT 2017, this poster outlines how OGT has optimised a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid 30 hybridisation step.
-
The use of a hybridisation-based NGS enrichment panel for the confident identification of a broad range of low frequency variants from as little as 50ng of challenging clinical research FFPE samples
Presented at AMP 2016, this poster outlines how the SureSeq FFPE DNA Repair Mix significantly improves NGS library yields, with an increase of mean target coverage (increased by >2.2 fold), resulting in more meaningful data.